Ultragenyx’s gene therapy meets co-primary endpoint in Phase III trial
Ultragenyx Pharmaceutical’s gene therapy for ornithine transcarbamylase (OTC) deficiency has shown benefit in a Phase III trial, hitting one of …
Post
-
-
Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial …
-
Virta Health reports improved outcomes in pancreatic cancer trial
Virta Health has reported improved outcomes from its Phase II randomised controlled trial (RCT), which examined the impact of its …
-
Pilatus Biosciences doses first patient in PLT012 antibody trial
Pilatus Biosciences has announced the dosing of the first patient in its Phase I clinical trial of PLT012, a first-in-class …
-
Illicit drug use associated with increased odds of stroke
According to the World Health Organization, stroke was the third leading cause of death and disability globally in 2021, and …
-
Preclinical data for MDL-001 indicates potential across multiple viral infections
Model Medicines presented an update on its lead candidate, MDL-001, at the Biocom Global Partnering Conference in California. MDL-001 is …
-
UCB’s Bimzelx bests Skyrizi in Phase III PsA study, but analysts sceptical
UCB’s top-selling drug Bimzelx (bimekizumab) has bested AbbVie’s blockbuster immunology drug, Skyrizi (risankizumab), during a head-to-head study in psoriatic arthritis …
-
Strong relationships among stakeholders key to clinical supply chain success
Pharmaceutical companies increasingly require more scalability and precision in managing their clinical supply chain. Such demands necessitate stronger, more impactful …
-
Patient enrolment concludes in Spinogenix’s Phase II schizophrenia trial
US-based biopharmaceutical company Spinogenix has concluded the enrolment of patients in its Phase II clinical trial of tazbentetol (previously known …
-
Biogen’s Spinraza successor benefits SMA patients unresponsive to gene therapy
Biogen’s successor to Spinraza (nusinersen) has shown benefit in spinal muscular atrophy (SMA) patients who had suboptimal clinical status despite …
-
Gesynta Pharma doses first patient in Phase II NOVA trial
Gesynta Pharma has dosed the first patient in its Phase II trial, NOVA, investigating vipoglanstat, a non-hormonal, non-opioid drug for …
-
Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
A constantly evolving landscape for clinical trials and drug development research has created challenges for the sector to not only …
-
UK health authorities join forces to champion foreign infectious disease trials
Health divisions within the UK government and British non-profit organisations have banded together to support infectious disease trials in Africa, …
-
EnteroBiotix completes enrolment in Phase IIa MAST trial
EnteroBiotix has announced the completion of enrolment in the Phase IIa MAST trial of EBX-102-02 in patients who are undergoing …
-
Kainova reports positive top line results from Phase I EPRAD trial
Canada-based Kainova Therapeutics has reported positive top line results from the Phase I EPRAD study of DT-9081, an oral EP4 …
